In the present study, we characterized TAS5315, a highly potent and selective BTK inhibitor, to evaluate its utility as a potential therapeutic drug for the treatment of RA by assessing its inhibitory effects on the functions of various effector cells associated with RA progression. The gene discussed is BTK; the disease is rheumatoid arthritis.